Literature DB >> 11709305

Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain.

E Pérez-Trallero1, C Fernández-Mazarrasa, C García-Rey, E Bouza, L Aguilar, J García-de-Lomas, F Baquero.   

Abstract

A nationwide multicenter susceptibility surveillance study which included 1,684 Streptococcus pneumoniae and 2,039 S. pyogenes isolates was carried out over 1 year in order to assess the current resistance patterns for the two most important gram-positive microorganisms responsible for community-acquired infections in Spain. Susceptibility testing was done by a broth microdilution method according to National Committee for Clinical Laboratory Standards M100-S10 interpretative criteria. For S. pneumoniae, the prevalences of highly resistant strains were 5% for amoxicillin and amoxicillin-clavulanic acid; 7% for cefotaxime; 22% for penicillin; 31% for cefuroxime; 35% for erythromycin, clarithromycin, and azithromycin; and 42% for cefaclor. For S. pyogenes, the prevalence of erythromycin resistance was 20%. Efflux was encountered in 90% of S. pyogenes and 5% of S. pneumoniae isolates that exhibited erythromycin resistance. Erythromycin resistance was associated with clarithromycin and azithromycin in both species, regardless of phenotype. Despite the different nature of the mechanisms of resistance, a positive correlation (r = 0.612) between the two species in the prevalence of erythromycin resistance was found in site-by-site comparisons, suggesting some kind of link with antibiotic consumption. Regarding ciprofloxacin, the MIC was >or=4 microg/ml for 7% of S. pneumoniae and 3.5% of S. pyogenes isolates. Ciprofloxacin resistance (MIC, >or=4 microg/ml) was significantly (P < 0.05) associated with macrolide resistance in both S. pyogenes and S. pneumoniae and with penicillin nonsusceptibility in S. pneumoniae.

Entities:  

Mesh:

Year:  2001        PMID: 11709305      PMCID: PMC90834          DOI: 10.1128/AAC.45.12.3334-3340.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  J Liñares; A G de la Campa; R Pallares
Journal:  N Engl J Med       Date:  1999-11-11       Impact factor: 91.245

2.  Influences of different factors on prevalence of ciprofloxacin resistance in Streptococcus pneumoniae in Spain.

Authors:  C García-Rey; L Aquilar; F Baquero
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

3.  Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990).

Authors:  J Liñares; R Pallares; T Alonso; J L Perez; J Ayats; F Gudiol; P F Viladrich; R Martin
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

4.  Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.

Authors:  B Rosón; J Carratalà; F Tubau; J Dorca; J Liñares; R Pallares; F Manresa; F Gudiol
Journal:  Microb Drug Resist       Date:  2001       Impact factor: 3.431

5.  Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997).

Authors:  J J Granizo; L Aguilar; J Casal; R Dal-Ré; F Baquero
Journal:  J Antimicrob Chemother       Date:  2000-12       Impact factor: 5.790

6.  Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland.

Authors:  H Seppälä; A Nissinen; Q Yu; P Huovinen
Journal:  J Antimicrob Chemother       Date:  1993-12       Impact factor: 5.790

7.  Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997).

Authors:  J J Granizo; L Aguilar; J Casal; C García-Rey; R Dal-Ré; F Baquero
Journal:  J Antimicrob Chemother       Date:  2000-11       Impact factor: 5.790

8.  Is there an ecological relationship between rates of antibiotic resistance of species of the genus Streptococcus? The Spanish Surveillance Group for Respiratory Pathogens.

Authors:  R Gómez-Lus; J J Granizo; L Aguilar; E Bouza; A Gutierrez; J García-de-Lomas
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

9.  The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta.

Authors:  J Hofmann; M S Cetron; M M Farley; W S Baughman; R R Facklam; J A Elliott; K A Deaver; R F Breiman
Journal:  N Engl J Med       Date:  1995-08-24       Impact factor: 91.245

10.  The emergence of erythromycin resistance in Streptococcus pyogenes in Fremantle, Western Australia.

Authors:  N Stingemore; G R Francis; M Toohey; D B McGechie
Journal:  Med J Aust       Date:  1989-06-05       Impact factor: 7.738

View more
  54 in total

1.  Genetic relatedness of recently collected Spanish respiratory tract Streptococcus pneumoniae isolates with reduced susceptibility to amoxicillin.

Authors:  E Pérez-Trallero; J M Marimón; A González; C García-Rey; L Aguilar
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

2.  Dissemination of emm28 erythromycin-, clindamycin- and bacitracin-resistant Streptococcus pyogenes in Spain.

Authors:  E Perez-Trallero; C Garcia; B Orden; J M Marimon; M Montes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-08       Impact factor: 3.267

3.  Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae.

Authors:  Luz Balsalobre; María José Ferrándiz; Josefina Liñares; Fe Tubau; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

4.  Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain.

Authors:  E Pérez-Trallero; C García-Rey; A M Martín-Sánchez; L Aguilar; J García-de-Lomas; J Ruiz
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

5.  Antimicrobial susceptibility patterns and macrolide resistance genes of beta-hemolytic streptococci in Korea.

Authors:  Young Uh; In Ho Jang; Gyu Yel Hwang; Mi Kyung Lee; Kap Jun Yoon; Hyo Youl Kim
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

6.  Resistance phenotypes and genotypes of erythromycin-resistant Streptococcus pneumoniae isolates in Beijing and Shenyang, China.

Authors:  Zhao Tiemei; Fang Xiangqun; Liu Youning
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

7.  Evolution and global dissemination of macrolide-resistant group A streptococci.

Authors:  D Ashley Robinson; Joyce A Sutcliffe; Wezenet Tewodros; Anand Manoharan; Debra E Bessen
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

8.  Streptococcus pyogenes pharyngeal isolates with reduced susceptibility to ciprofloxacin in Spain: mechanisms of resistance and clonal diversity.

Authors:  Sebastián Albertí; Guadalupe Cortés; Cesar García-Rey; Carmen Rubio; Fernando Baquero; José Angel García-Rodríguez; Emilio Bouza; Lorenzo Aguilar
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

9.  Incidence, epidemiology, and characteristics of quinolone-nonsusceptible Streptococcus pneumoniae in Croatia.

Authors:  Glenn A Pankuch; Bülent Bozdogan; Kensuke Nagai; Arjana Tambić-Andrasević; Slavko Schoenwald; Tera Tambić; Smilja Kalenić; Sanja Plesko; Nastja K Tepes; Zdenka Kotarski; Marina Payerl-Pal; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  Molecular epidemiology of macrolide-resistant Streptococcus pneumoniae isolates in Europe.

Authors:  Ralf René Reinert; Adrian Ringelstein; Mark van der Linden; Murat Yücel Cil; Adnan Al-Lahham; Franz-Josef Schmitz
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.